Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 28 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Study of Dasatinib in Patients With Chronic Phase CML and a Suboptimal Response to Imatinib

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				CA180-043 EUDRACT Number: 2005-005153-22, NCT00320190


2.		Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 90				Pharmaceutical / Industry				CA180-034 NCT00123474


3.		Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				20 to 75				Pharmaceutical / Industry				CA180-031 NCT00337454


4.		A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				20 to 75				Pharmaceutical / Industry				CA180-138 NCT00482703


5.		Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				CA180-015 NCT00101595


6.		Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				CA180-005 NCT00101647


7.		Study of BMS-354825 in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				CA180-013 NCT00101660


8.		Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				CA180-006 NCT00101816

Last Modified: 5/24/2007 First Published: 4/7/2005


9.		Phase II Study of BMS-354825 in Patients With Imatinib Mesylate-Resistant or -Intolerant Blastic Phase Chronic Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0411069-01 BMS-CA180006, EUDRACT-2004-002516-28, NCT00108719

Last Modified: 5/24/2007 First Published: 4/23/2005


10.		Phase II Study of BMS-354825 in Patients With Imatinib Mesylate-Resistant or -Intolerant Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0411071-01 BMS-CA180015, EUDRACT-2004-002517-36, NCT00110097

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute